American Board of Forensic Dentistry

Commenting on the planned consolidation, Thomas Bologna, president and chief executive officer of Orchid Cellmark, said: "The consolidation of our Nashville operations into Dallas will enhance our U.S.-based, forensics testing efficiencies and scalability, while bringing all of our forensics operations under one roof. Currently, we process most of our forensic casework samples in Dallas, and now our CODIS operations will move into this larger forensics operation. The Dallas facility permits us to add space and equipment to accommodate the added CODIS business. This consolidation makes sense for a number of strategic, financial and pragmatic reasons, and represents the latest in our ongoing initiatives to provide high quality DNA forensic testing services in an ever increasing cost effective structure."

Mr. Bologna added, "We expect to realize approximately $1.4 million in annual cost savings from operational efficiencies, reduction in lease and equipment expenses, and increased scalability. We anticipate that one-time consolidation costs will be approximately $1.2 million. We plan to add at least twenty new positions at the Dallas facility to support the increased workload, including a number of transfers from the Nashville facility."